These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 25823907)
1. Characterizing opioid withdrawal during double-blind buprenorphine detoxification. Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. Dunn KE; Tompkins DA; Bigelow GE; Strain EC JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791 [TBL] [Abstract][Full Text] [Related]
4. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017 [TBL] [Abstract][Full Text] [Related]
5. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Sanders NC; Mancino MJ; Gentry WB; Guise JB; Bickel WK; Thostenson J; Oliveto AH Exp Clin Psychopharmacol; 2013 Aug; 21(4):294-302. PubMed ID: 23855333 [TBL] [Abstract][Full Text] [Related]
6. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder. Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432 [TBL] [Abstract][Full Text] [Related]
7. Spontaneous reductions in smoking during double-blind buprenorphine detoxification. Patrick ME; Dunn KE; Badger GJ; Heil SH; Higgins ST; Sigmon SC Addict Behav; 2014 Sep; 39(9):1353-6. PubMed ID: 24845165 [TBL] [Abstract][Full Text] [Related]
8. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. Nielsen S; Hillhouse M; Thomas C; Hasson A; Ling W J Addict Med; 2013; 7(1):33-8. PubMed ID: 23222095 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C; Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007 [TBL] [Abstract][Full Text] [Related]
10. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. Tompkins DA; Smith MT; Mintzer MZ; Campbell CM; Strain EC J Pharmacol Exp Ther; 2014 Feb; 348(2):217-26. PubMed ID: 24227768 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Webster L; Hjelmström P; Sumner M; Gunderson EW J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785 [TBL] [Abstract][Full Text] [Related]
12. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Dunn KE; Sigmon SC; Strain EC; Heil SH; Higgins ST Drug Alcohol Depend; 2011 Dec; 119(1-2):1-9. PubMed ID: 21741781 [TBL] [Abstract][Full Text] [Related]
13. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435 [TBL] [Abstract][Full Text] [Related]
15. Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation. Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE Psychopharmacology (Berl); 2008 Jun; 198(2):149-58. PubMed ID: 18327673 [TBL] [Abstract][Full Text] [Related]
16. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251 [TBL] [Abstract][Full Text] [Related]
17. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. Northrup TF; Stotts AL; Green C; Potter JS; Marino EN; Walker R; Weiss RD; Trivedi M Addict Behav; 2015 Feb; 41():20-8. PubMed ID: 25282598 [TBL] [Abstract][Full Text] [Related]
18. Relationship between opioid cross-tolerance during buprenorphine stabilization and return to opioid use during buprenorphine dose tapering. Greenwald MK; Sogbesan T; Moses TEH Psychopharmacology (Berl); 2024 Jun; 241(6):1151-1160. PubMed ID: 38326506 [TBL] [Abstract][Full Text] [Related]